Meta-analysis of microRNAs as biomarkers for muscle-invasive bladder cancer

Biomedical Reports

Volumn 5, Issue 2, 2016, Pages 159-164

  Zheng, Lin Feng ^a   Sun, Wen Yong ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Biomarker; Diagnosis; Meta analysis; MicroRNA; Muscle invasive bladder cancer

Indexed keywords

MICRORNA;

ARTICLE; CANCER RISK; DIAGNOSTIC ACCURACY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HISTOLOGY; HUMAN; META ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; ODDS RATIO; PUBLICATION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY;

EID: 85019113715     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.705     Document Type: Article

References (34)

1. Knowles MA and Hurst CD: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer 15: 25-41, 2015.
2. Xu S, Zhang GM, Guan FJ, Dong DH, Luo L, Li B, Ma XC, Zhao J and Sun LJ: The association between metabolic syndrome and the risk of urothelial carcinoma of the bladder: A case-control study in China. World J Surg Oncol 13: 236, 2015.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
4. Rocken C and Behrens HM: Validating the prognostic and discriminating value of the TNM-classification for gastric cancer - a critical appraisal. Eur J Cancer 51: 577-586, 2015.
5. Eble JN, Sauter G, Epstein JI and Sesterhen IA (eds): World Health Organization Classification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon, 2004.
6. Soloway MS: Bladder cancer: Lack of progress in bladder cancer - what are the obstacles? Nat Rev Urol 10: 5-6, 2013.
7. Chamie K and Litwin MS: Quality of bladder cancer care in the USA. Expert Rev Pharmacoecon Outcomes Res 11: 619-621, 2011.
8. Corcoran AT, Handorf E, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A and Smaldone MC: Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int 115: 230-237, 2015.
9. Jayaratna IS, Navai N and Dinney CP: Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol 4: 273-282, 2015.
10. Johnson DC, Greene PS and Nielsen ME: Surgical advances in bladder cancer: At what cost? Urol Clin North Am 42: 235-252, ix, 2015.
11. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
12. Beitzinger M and Meister G: Preview. MicroRNAs: From decay to decoy. Cell 140: 612-614, 2010.
13. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
14. Kent OA and Mendell JT: A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006.
15. Maida Y, Takakura M, Nishiuchi T, Yoshimoto T and Kyo S: Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium. Cancer Med 5: 304-314, 2016.
16. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, et al: Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12: 655-664, 2016.
17. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, et al: Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69: 8472-8481, 2009.
18. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, et al: MicroRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132: 2479-2491, 2013.
19. Segersten U, Spector Y, Goren Y, Tabak S and Malmström PU: The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer. Urol Oncol 32: 613-618, 2014.
20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt PM; QUADAS-2 Group: QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155: 529-536, 2011.
21. Dinnes J, Deeks J, Kirby J and Roderick P: A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9: 1-113, iii, 2005.
22. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, et al: miRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124: 2236-2242, 2009.
23. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D and Bieche I: MicroRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature predictive of aggressiveness and prognosis of muscle-invasive bladder cancer. Eur Urol Suppl 11: e169, 2012.
24. Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, Amsellem-Ouazana D and Bieche I: Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer 106: 1177-1186, 2012.
25. Adam L, Wszolek MF, Liu CG, Jing W, Diao L, Zien A, Zhang JD, Jackson D and Dinney CP: Plasma microRNA profiles for bladder cancer detection. Urol Oncol 31: 1701-1708, 2013.
26. Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, et al: miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn 15: 695-705, 2013.
27. Li H, Yu G, Shi R, Lang B, Chen X, Xia D, Xiao H, Guo X, Guan W, Ye Z, et al: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer 13: 8, 2014.
28. Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG and Scorilas A: Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis 36: 528-537, 2015.
29. Wang J, Zhang X, Wang L, Dong Z, Du L, Yang Y, Guo Y and Wang C: Downregulation of urinary cell-free microRNA-214 as a diagnostic and prognostic biomarker in bladder cancer. J Surg Oncol 111: 992-999, 2015.
30. Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao YC, Xu LW, Yang XB, Geng LG, Dou QL, et al: MicroRNA expression profiles in muscle-invasive bladder cancer: Identification of a four-microRNA signature associated with patient survival. Tumour Biol 36: 8159-8166, 2015.
31. Fang Z, Dai W, Wang X, Chen W, Shen C, Ye G and Li L: Circulating miR-205: A promising biomarker for the detection and prognosis evaluation of bladder cancer. Tumour Biol 37: 8075-8082, 2016.
32. Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R, et al: The application of artificial intelligence to microarray data: Identification of a novel gene signature to identify bladder cancer progression. Eur Urol 57: 398-406, 2010.
33. Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, Henrique R and Jerónimo C: MicroRNA profile: A promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 109: 2646-2653, 2013.
34. Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, et al: Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 136: 854-862, 2015.